These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 6112126)

  • 1. Detection of dopaminergic supersensitivity induced by neuroleptic drugs in mice.
    Yen-Koo HC; Balazs T
    Drug Chem Toxicol; 1980; 3(2):237-47. PubMed ID: 6112126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of dopaminergic agonist-induced gnawing behavior by neuroleptic drugs in mice.
    Yen-Koo HC; Davis DA; Balazs T
    Drug Chem Toxicol; 1985; 8(6):495-502. PubMed ID: 2868876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pathophysiology of tardive dyskinesia.
    Klawans HL; Carvey P; Tanner CM; Goetz CG
    J Clin Psychiatry; 1985 Apr; 46(4 Pt 2):38-41. PubMed ID: 2858479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebral dopamine function in rats following withdrawal from one year of continuous neuroleptic administration.
    Clow A; Theodorou A; Jenner P; Marsden CD
    Eur J Pharmacol; 1980 May; 63(2-3):145-57. PubMed ID: 6103814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopaminergic supersensitivity after neuroleptics: time-course and specificity.
    Muller P; Seeman P
    Psychopharmacology (Berl); 1978 Dec; 60(1):1-11. PubMed ID: 32574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential enhancement of locomotor activity by dopamine agonists following chronic neuroleptic treatment: an animal model of tardive dyskinesia.
    Tye NC; Horsman L; Wright FC; Pullar IA
    Eur J Pharmacol; 1979 Apr; 55(1):103-7. PubMed ID: 35357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Supersensitivity to dopaminergic agonists induced by haloperidol.
    Thornburg JE; Moore KE
    Natl Inst Drug Abuse Res Monogr Ser; 1975 Nov; (3):23-8. PubMed ID: 1241913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alterations in sleep polygraphy after neuroleptic withdrawal: a putative supersensitive dopaminergic mechanism.
    Thaker GK; Wagman AM; Kirkpatrick B; Tamminga CA
    Biol Psychiatry; 1989 Jan; 25(1):75-86. PubMed ID: 2563233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A monitoring test for the liability of neuroleptic drugs to induce tardive dyskinesia.
    Gunne LM; Bárány S
    Psychopharmacology (Berl); 1979 Jun; 63(3):195-8. PubMed ID: 39307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential liabilities of haloperidol and thioridazine for inducing apomorphine hypersensitivity.
    De Veaugh-Geiss J; Devanand DP; Carey RJ
    Biol Psychiatry; 1982 Nov; 17(11):1289-301. PubMed ID: 6891268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molindone and haloperidol in tardive dyskinesia.
    Glazer WM; Hafez HM; Benarroche CL
    J Clin Psychiatry; 1985 Aug; 46(8 Pt 2):4-7. PubMed ID: 2862139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe cases of neuroleptic-induced supersensitivity psychosis. Diagnostic criteria for the disorder and its treatment.
    Chouinard G
    Schizophr Res; 1991; 5(1):21-33. PubMed ID: 1677263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term haloperidol treatment (but not risperidone) enhances addiction-related behaviors in mice: role of dopamine D2 receptors.
    Carvalho RC; Fukushiro DF; Helfer DC; Callegaro-Filho D; Trombin TF; Zanlorenci LH; Sanday L; Silva RH; Frussa-Filho R
    Addict Biol; 2009 Jul; 14(3):283-93. PubMed ID: 19298320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iron modulates neuroleptic-induced effects related to the dopaminergic system.
    Ben-Shachar D; Livne E; Spanier I; Zuk R; Youdim MB
    Isr J Med Sci; 1993 Sep; 29(9):587-92. PubMed ID: 7901181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dogma disputed: is tardive dyskinesia due to postsynaptic dopamine receptor supersensitivity?
    Jeste DV; Wyatt RJ
    J Clin Psychiatry; 1981 Dec; 42(12):455-7. PubMed ID: 6118358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics.
    Chouinard G; Jones BD
    Am J Psychiatry; 1980 Jan; 137(1):16-21. PubMed ID: 6101522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spontaneous orofacial dyskinesia and dopaminergic function in rats after 6 months of neuroleptic treatment.
    Waddington JL; Cross AJ; Gamble SJ; Bourne RC
    Science; 1983 Apr; 220(4596):530-2. PubMed ID: 6132447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative neurochemical changes associated with chronic administration of typical and atypical neuroleptics: implications in tardive dyskinesia.
    Bishnoi M; Kumar A; Chopra K; Kulkarni SK
    Indian J Exp Biol; 2007 Feb; 45(2):175-9. PubMed ID: 17375557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Classification of neuroleptics: implications for tardive dyskinesia.
    Christensen AV
    Pol J Pharmacol Pharm; 1985; 37(3):295-309. PubMed ID: 2866499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in dopamine-mediated behaviour during one year's neuroleptic administration.
    Clow A; Jenner P; Marsden CD
    Eur J Pharmacol; 1979 Aug; 57(4):365-75. PubMed ID: 39769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.